Clinically Approved Antibiotics from 2010 to 2022

2023/04/26 by Erik Jung, Karl Gademann

paper · doi:10.2533/chimia.2023.230

crossref issued 2023/04/26 · crossref published 2023/04/26 · crossref published-online 2023/04/26 · crossref created 2023/04/26 · crossref deposited 2023/04/26 · crossref indexed 2026/07/31

Abstract

This review discusses small molecule antibiotics approved for clinical use in the time frame 2010-2022. This time span saw the approval of four synthetic antibiotics (bedaquiline, pretomanid, delafloxacin, tedizolid), nine natural product derivatives (ceftaroline fosamil, cefiderocol, plazomicin, omadacycline, eravacycline, sarecycline, lefamulin, dalbavancin, oritavancin), and one natural product (fidaxomicin).

Related

• The past, present, and future of antibiotics
• Three innovations of next-generation antibiotics: evolvability, specificity, and non-immunogenicity
• A Review of Antibacterial Candidates with New Modes of Action
• Antibiotic resistance in microbes: History, mechanisms, therapeutic strategies and future prospects
• New Perspectives on Antimicrobial Agents: Omadacycline for community-acquired pneumonia, skin and soft tissue infections, and nontuberculous mycobacteria (focus on M. abscessus )